Ally Bridge Group (NY) LLC Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001822947
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 22 positions · Total reported value $179.89M · Top-10 concentration 65.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 75.9% · 4 new · 6 cut · 12 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -15.8% · vs SPY -17.9% · Prev Value $113.07M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -16.4% · vs SPY -18.5% · Latest Value $75.30M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2024 13F filing, Ally Bridge Group (NY) LLC disclosed 22 equity positions with a combined reported value of $179.89M. The filing implies a focused portfolio: its ten largest positions account for 65.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2024 were BPMC ($15.27M), SLNO ($14.40M), CGON ($14.06M). By sector, the heaviest allocations are Health Care 47.3%, Other 52.7%. Versus the prior quarter, allocation shifted toward Other (+9.0pp) and away from Health Care (-9.0pp).
Versus the prior quarter, Ally Bridge Group (NY) LLC opened 4 new positions, trimmed 6 and fully exited 12, a turnover rate of 75.9% of positions. The portfolio's overlap with the prior quarter was 29% of names.
The largest new positions opened in Q1 2024 were BPMC ($15.27M), CGON ($14.06M), VRNA ($11.85M).
Of the 12 positions fully exited versus the prior quarter, the largest were ARGX ($13.32M), CBAY ($11.57M), ITCI ($10.12M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2024)
- BPMC BLUEPRINT MEDICINES CORP · $15.27M
- CGON CG ONCOLOGY INC · $14.06M
- VRNA VERONA PHARMA PLC · $11.85M
- MNMD MIND MEDICINE MINDMED INC · $9.41M
- KURA KURA ONCOLOGY INC · $7.79M
- INSM INSMED INC · $6.78M
- DNTH DIANTHUS THERAPEUTICS INC · $6.51M
- LYRA LYRA THERAPEUTICS INC · $6.24M
Fully Exited (vs previous quarter)
- ARGX ARGENX SE · prev qtr: $13.32M
- CBAY CYMABAY THERAPEUTICS INC · prev qtr: $11.57M
- ITCI INTRA-CELLULAR THERAPIES INC · prev qtr: $10.12M
- APLS APELLIS PHARMACEUTICALS INC · prev qtr: $8.98M
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $8.66M
- AXSM AXSOME THERAPEUTICS INC. · prev qtr: $8.03M
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $6.81M
- AMAM AMBRX BIOPHARMA INC · prev qtr: $5.49M
Insider Transactions (Form 4)
Latest Ally Bridge Group (NY) LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Ally Bridge Group (NY) LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 17 US equity positions with a combined value of $75.30M. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-121984 (status: Approved), registered 2021-07-30
- Regulatory AUM (Form ADV): $218.95M as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 3 hedge funds
Portfolio Structure
- 17 positions · $75.30M reported value (Q3 2026)
- Top 10 holdings = 88.8% of reported value
- Largest position: DFTX (DEFINIUM THERAPEUTICS INC) at 20.2%
- Average position size: $4.43M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 4 new, 2 added, 6 reduced, 12 exited
- 5 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
160.95K | $15.27M | 8.49% | New | |
| 2 |
|
336.49K | $14.40M | 8.01% | Add | |
| 3 |
|
320.38K | $14.06M | 7.82% | New | |
| 4 |
|
309.37K | $13.32M | 7.40% | Add | |
| 5 |
|
736.74K | $11.85M | 6.59% | New | |
| 6 |
|
255.93K | $11.52M | 6.41% | Reduce | |
| 7 |
|
159.49K | $9.73M | 5.41% | Add | |
| 8 |
|
1.00M | $9.41M | 5.23% | New | |
| 9 |
|
547.04K | $9.24M | 5.14% | Add | |
| 10 |
|
2.76M | $9.11M | 5.06% | Reduce | |
| 11 |
|
289.94K | $8.51M | 4.73% | Reduce | |
| 12 |
|
365.04K | $7.79M | 4.33% | New | |
| 13 |
|
250.00K | $6.78M | 3.77% | New | |
| 14 |
|
216.97K | $6.51M | 3.62% | New | |
| 15 |
|
559.03K | $6.33M | 3.52% | Reduce | |
| 16 |
|
1.00M | $6.24M | 3.47% | New | |
| 17 |
|
270.56K | $5.84M | 3.25% | New | |
| 18 |
|
420.00K | $3.77M | 2.10% | New | |
| 19 |
|
801.44K | $3.59M | 2.00% | New | |
| 20 |
|
394.77K | $3.57M | 1.98% | New | |
| 21 |
|
1.06M | $2.02M | 1.12% | Reduce | |
| 22 |
|
725.95K | $1.00M | 0.56% | Hold | |
FAQ
What did Ally Bridge Group (NY) LLC buy in 2024-Q1?
In its 2024-Q1 13F filing, Ally Bridge Group (NY) LLC reported 22 equity positions worth $179.89M in aggregate; its largest disclosed positions were BPMC ($15.27M), SLNO ($14.40M), CGON ($14.06M).
How large is Ally Bridge Group (NY) LLC's portfolio?
Ally Bridge Group (NY) LLC reported $179.89M of long equity holdings across 22 positions as of 2024-Q1. Top-10 holdings account for 65.6% of reported value.
What is Ally Bridge Group (NY) LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.